Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Average Recommendation of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.00.

A number of research analysts recently weighed in on TEVA shares. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Barclays upped their price objective on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, June 5th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th.

Teva Pharmaceutical Industries Stock Up 1.5 %

TEVA opened at $16.80 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $7.42 and a 52 week high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The firm has a 50-day simple moving average of $16.21 and a two-hundred day simple moving average of $13.82. The company has a market capitalization of $19.03 billion, a PE ratio of -40.98, a price-to-earnings-growth ratio of 1.54 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The firm had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. Analysts forecast that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Amir Weiss sold 15,500 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the sale, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at $299,275.20. The disclosure for this sale can be found here. Insiders sold 549,719 shares of company stock worth $9,353,736 over the last 90 days. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in shares of Teva Pharmaceutical Industries by 705.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after buying an additional 507,568 shares during the period. SG Americas Securities LLC increased its position in Teva Pharmaceutical Industries by 31.7% during the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after purchasing an additional 131,043 shares during the period. Wellington Management Group LLP raised its holdings in shares of Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after purchasing an additional 102,261 shares in the last quarter. Gateway Investment Advisers LLC lifted its position in shares of Teva Pharmaceutical Industries by 28.6% in the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after purchasing an additional 9,312 shares during the period. Finally, Public Employees Retirement Association of Colorado boosted its stake in shares of Teva Pharmaceutical Industries by 1,382.8% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after purchasing an additional 238,573 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.